Answers are grounded in this paper and cite their sources.
Background Falls are a safety concern during androgen receptor pathway inhibitor (ARPI) treatment for prostate cancer, but post-marketing pharmacovigilance studies specifically focused on fall events remain limited. This study aimed to evaluate disproportionality in fall reporting for four ARPIs: abiraterone, enzalutamide, apalutamide, and darolutamide. Methods We conducted a pharmacovigilance study using individual case safety reports (ICSRs) for males aged ≥50 years reported during the common reporting window of 2019Q3–2026Q2 in the FDA Adverse Event Monitoring System (AEMS) database. Signals of disproportionate reporting in the primary analysis were detected using the reporting odds ratio (ROR) and information component (IC). Signal consistency was examined through subgroup analyses, sensitivity analyses, and multivariable logistic regression analysis. An exploratory statistical interaction screen based on drug co-reporting was conducted, and time-to-onset patterns were evaluated separately. Results In the primary analysis, enzalutamide (ROR: 2.47, 95% CI: 2.21–2.75; IC 025 : 1.09), apalutamide (ROR: 1.59, 95% CI: 1.35–1.88; IC 025 : 0.41), and abiraterone (ROR: 1.47, 95% CI: 1.30–1.65; IC 025 : 0.36) met the predefined signal criteria, whereas darolutamide did not (ROR: 1.25, 95% CI: 0.96–1.63; IC 025 : −0.08). Enzalutamide met signal criteria in all four sensitivity analyses; apalutamide and abiraterone did not meet them under indication restriction, and darolutamide met them only when secondary-suspect reports were included. Adjusted analyses supported enzalutamide (aROR: 1.47, 95% CI: 1.31–1.65) and apalutamide (aROR: 1.23, 95% CI: 1.03–1.47), but not abiraterone or darolutamide. No evaluated ARPI-docetaxel or ARPI-PARP inhibitor combination met the predefined Ω signal criterion (Ω 025 > 0). However, Fall co-reports were sparse (0–10 per combination), limiting interpretation of these findings. Non-detection of an Ω signal should not be taken as evidence that clinically relevant interactions are absent. Median time to onset was 64 days for enzalutamide, 74 days for apalutamide, and 205 days for abiraterone, with early-failure patterns in Weibull analyses. Conclusion The enzalutamide and apalutamide signals reproduced previously documented Fall associations, whereas the abiraterone and darolutamide findings varied across analysis conditions. These findings should be interpreted as pharmacovigilance signals that may help prioritize fall-related safety concerns, rather than as direct estimates of clinical risk.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: